

# Resource Summary Report

Generated by [NIF](#) on Sep 3, 2026

## Mouse IgG2b, k

RRID:AB\_396928

Type: Antibody

---

### Proper Citation

BD Biosciences Cat# 557903, RRID:AB\_396928

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_396928](http://antibodyregistry.org/AB_396928)

**Proper Citation:** BD Biosciences Cat# 557903, RRID:AB\_396928

**Target Antigen:** Mouse IgG2b k

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** vendor suggested use: IgG2; IgG2 Flow Cytometry, Intracellular Staining (Flow), Isotype Control; Immunocytochemistry; Flow Cytometry; Other; Vendor suggested use: IgG2; IgG2 Flow Cytometry, Intracellular Staining (Flow), Isotype Control; Immunocytochemistry; Flow Cytometry; Other

**Antibody Name:** Mouse IgG2b, k

**Description:** This monoclonal targets Mouse IgG2b k

**Antibody ID:** AB\_396928

**Vendor:** BD Biosciences

**Catalog Number:** 557903

**Record Creation Time:** 20231110T081143+0000

**Record Last Update:** 20260830T023920+0000

---

### Ratings and Alerts

No rating or validation information has been found for Mouse IgG2b, k.

No alerts have been found for Mouse IgG2b, k.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Mohammadi N, et al. (2025) Sympathetic neurons can modify the intrinsic structural and functional properties of human pluripotent stem cell-derived cardiomyocytes. The Journal of physiology, 603(7), 2089.

Kattelus R, et al. (2024) Phenotypic profiling of human induced regulatory T cells at early differentiation: insights into distinct immunosuppressive potential. Cellular and molecular life sciences : CMLS, 81(1), 399.

Buchacher T, et al. (2023) PIM kinases regulate early human Th17 cell differentiation. Cell reports, 42(12), 113469.

Abou-Hamad J, et al. (2022) CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness. iScience, 25(12), 105524.

Choi MY, et al. (2018) Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell stem cell, 22(6), 951.